Cytokine therapy in dermatology

被引:23
作者
Asadullah, K [1 ]
Sterry, W
Trefzer, U
机构
[1] Schering AG, Res Business Area Dermatol, D-13342 Berlin, Germany
[2] Humboldt Univ, Univ Hosp Charite, Dept Dermatol & Allergy, D-10098 Berlin, Germany
关键词
immunomodulation; interferons; interleukins;
D O I
10.1034/j.1600-0625.2002.110201.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Cytokines have been in the focus of scientific interest for some years now. Analysing their expression permitted a better understanding of the pathogenesis of various diseases, including in dermatology. Moreover, they are now far beyond the stage when they were of interest only to the pathophysiological research sector: some cytokine therapies are already being employed as part of the clinical practice. In fact, several cytokines are used for the treatment of malignant, inflammatory and infectious skin diseases. Their stage of development ranges from advanced, already approved and well established therapies (e.g. IFN-alpha and IL-2 for melanoma) to early explorative trials (e.g. IL-4 and IL-10 for psoriasis). Some of the new approaches currently under investigation will actually lead to registration of new drugs for dermatological treatment and to supplement existing therapeutic options. Beside this, the results of clinical trials with cytokines are significantly contributing to our understanding of the pathophysiology of diseases. They will give a better insight into which mechanisms play a greater or lesser part in their development and may generate momentum for still better targeted pharmacological approaches. Here we would like to give an overview about the current stage of cytokine therapy and the prospects for dermatological indications. The terminology and immunobiology of cytokines are also briefly discussed, since for a sensible interpretation of the relevant findings a basic knowledge of these biologically highly active messenger substances is essential.
引用
收藏
页码:97 / 106
页数:10
相关论文
共 67 条
  • [1] Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93
  • [2] Asadullah K, 1999, DRUG TODAY, V35, P913
  • [3] Cytokine determination
    Asadullah, K
    Docke, WD
    Reinke, P
    Sterry, W
    Volk, HD
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1997, 122 (46) : 1424 - 1431
  • [4] Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin 10 mRNA
    Asadullah, K
    Docke, WD
    Haeussler, A
    Sterry, W
    Volk, HD
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (06) : 833 - 837
  • [5] Cytokines and cutaneous T-cell lymphomas
    Asadullah, K
    Docke, WD
    Volk, HD
    Sterry, W
    [J]. EXPERIMENTAL DERMATOLOGY, 1998, 7 (06) : 314 - 320
  • [6] Novel immunotherapies for psoriasis
    Asadullah, K
    Volk, HD
    Sterry, W
    [J]. TRENDS IN IMMUNOLOGY, 2002, 23 (01) : 47 - 53
  • [7] IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach
    Asadullah, K
    Sterry, W
    Stephanek, K
    Jasulaitis, D
    Leupold, M
    Audring, H
    Volk, HD
    Döcke, WD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) : 783 - 794
  • [8] Effects of systemic interleukin-10 therapy on psoriatic skin lesions:: Histologic, immunohistologic, and molecular biology findings
    Asadullah, K
    Friedrich, M
    Hanneken, S
    Rohrbach, C
    Audring, H
    Vergopoulos, A
    Ebeling, M
    Döcke, WD
    Volk, HD
    Sterry, W
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (05) : 721 - 727
  • [9] Interleukin 10 treatment of psoriasis -: Clinical results of a phase 2 trial
    Asadullah, K
    Döcke, WD
    Ebeling, M
    Friedrich, M
    Belbe, G
    Audring, H
    Volk, HD
    Sterry, W
    [J]. ARCHIVES OF DERMATOLOGY, 1999, 135 (02) : 187 - 192
  • [10] Interleukin-10 in cutaneous disorders:: implications for its pathophysiological importance and therapeutic use
    Asadullah, K
    Sabat, R
    Wiese, A
    Döcke, WD
    Volk, HD
    Sterry, W
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 1999, 291 (12) : 628 - 636